- Home
- PMVP vs NRXP Comparison
PMVP vs NRXP Comparison
Compare PMVP & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMVP | NRXP |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 70.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PMVP | NRXP |
|---|---|---|
| Price | $1.19 | $2.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $5.00 | ★ $30.67 |
| AVG Volume (30 Days) | 217.0K | ★ 583.2K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $821.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $1.58 |
| 52 Week High | $1.84 | $6.01 |
Technical Indicators
Market Signals| Indicator | PMVP | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 45.80 |
| Support Level | $1.20 | $2.33 |
| Resistance Level | $1.26 | $2.48 |
| Average True Range (ATR) | 0.05 | 0.18 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 47.16 | 26.35 |
Price Performance
Historical ComparisonAbout PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.